Imfinzi combination improves PFS in liver cancer
09 November 2023 Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial First global Phase III trial to show improved clinical outcome for systemic therapyin combination with transarterial chemoembolisation (TACE) in this setting Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in